1.Harrison SA,
Neuschwander-Tetri BA.
Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Clin Liver Dis.
2004 Nov;8(4):861–79,
ix.
2.Ratziu V,
Bellentani S,
Cortez-Pinto H,
Day C,
Marchesini G.
A position statement on NAFLD/NASH based on the EASL 2009 special conference.
Journal of Hepatology.
2010 Aug;53(2):372–84.
3.Stamatakis E,
Primatesta P,
Chinn S,
Rona R,
Falascheti E.
Overweight and obesity trends from 1974 to 2003 in English children: what is the role of socioeconomic factors? Arch Dis Child.
2005 Oct;90(10):999–1004.
4.Wong RJ,
Aguilar M,
Cheung R,
Perumpail RB,
Harrison SA,
Younossi ZM,
et al.
Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.
Gastroenterology.
2015 Mar;148(3):547–55.
5.Talwalkar JA.
Motion - all patients with NASH need to have a liver biopsy: arguments for the motion.
Can J Gastroenterol.
2002 Oct;16(10):718–21.
6.Thampanitchawong P,
Piratvisuth T.
Liver biopsy:complications and risk factors.
World J Gastroenterol.
1999 Aug;5(4):301–4.T
7.Piccinino F,
Sagnelli E,
Pasquale G,
Giusti G.
Complications following percutaneous liver biopsy.
A multicentre retrospective study on 68,276 biopsies.
J Hepatol.
1986;2(2):165–73.
8.Terjung B,
Lemnitzer I,
Dumoulin FL,
Effenberger W,
Brackmann HH,
Sauerbruch T,
et al.
Bleeding complications after percutaneous liver biopsy.
An analysis of risk factors.
Digestion.
2003;67(3):138–45.
9.Standish RA,
Cholongitas E,
Dhillon A,
Burroughs AK,
Dhillon AP.
An appraisal of the histopathological assessment of liver fibrosis.
Gut.
2006 Apr 1;55(4):569–78.
10.Kleiner DE,
Brunt EM,
Van Natta M,
Behling C,
Contos MJ,
Cummings OW,
et al.
Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
Hepatology.
2005 Jun;41(6):1313–21.
11.Poynard T,
Munteanu M,
Deckmyn O,
Ngo Y,
Drane F,
Castille JM,
et al.
Validation of liver fibrosis biomarker (FibroTest) for assessing liver fibrosis progression: Proof of concept and first application in a large population.
Journal of Hepatology.
2012 Sep;57(3):541–8.
12.Friedrich-Rust M,
Ong M-F,
Martens S,
Sarrazin C,
Bojunga J,
Zeuzem S,
et al.
Performance of transient elastography for the staging of liver fibrosis: a meta-analysis.
Gastroenterology.
2008 Apr;134(4):960–74.
13.Cheng J,
Hou J,
Ding H,
Chen G,
Xie Q,
Wang Y,
et al.
Validation of Ten Noninvasive Diagnostic Models for Prediction of Liver Fibrosis in Patients with Chronic Hepatitis B.
PLoS One [Internet].
2015 Dec 28 [cited 2016 Jan 24];10(12).
14.Le Bihan D,
Breton E,
Lallemand D,
Aubin ML,
Vignaud J,
Laval-Jeantet M.
Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.
Radiology.
1988 Aug 1;168(2):497–505.
15.Luciani A,
Vignaud A,
Cavet M,
Nhieu JTV,
Mallat A,
Ruel L,
et al.
Liver cirrhosis: intravoxel incoherent motion MR imaging--pilot study.
Radiology.
2008 Dec;249(3):891–9.
16.Chow AM,
Gao DS,
Fan SJ,
Qiao Z,
Lee FY,
Yang J,
et al.
Liver fibrosis: an intravoxel incoherent motion (IVIM) study.
J Magn Reson Imaging.
2012 Jul;36(1):159–67.
17.Guiu B,
Petit J-M,
Capitan V,
Aho S,
Masson D,
Lefevre P-H,
et al.
Intravoxel incoherent motion diffusion-weighted imaging in nonalcoholic fatty liver disease: a 3.0-T MR study.
Radiology.
2012 Oct;265(1):96–103.
18.Leporq B,
Saint-Jalmes H,
Rabrait C,
Pilleul F,
Guillaud O,
Dumortier J,
et al.
Optimization of intra-voxel incoherent motion imaging at 3.0 Tesla for fast liver examination.
J Magn Reson Imaging.
2015 May;41(5):1209–17.
19.Leporq B,
Ratiney H,
Pilleul F,
Beuf O.
Liver fat volume fraction quantification with fat and water T1 and T 2* estimation and accounting for NMR multiple components in patients with chronic liver disease at 1.5 and 3.0 T.
Eur Radiol.
2013 Aug;23(8):2175–86.
20.Leporq B,
Lambert SA,
Ronot M,
Vilgrain V,
Van Beers BE.
Quantification of the triglyceride fatty acid composition with 3.0 T MRI.
NMR Biomed.
2014 Oct;27(10):1211–21.
21.Szczepaniak LS,
Nurenberg P,
Leonard D,
Browning JD,
Reingold JS,
Grundy S,
et al.
Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.
Am J Physiol Endocrinol Metab.
2005 Feb;288(2):E462–8.
22.Guiu B,
Loffroy R,
Petit JM,
Masson D,
Hillon P,
Cercueil JP,
et al.
[Fast technique to quantify liver steatosis at 3T: principles,
parametric imaging and applications].
J Radiol.
2009 Nov;90(11 Pt 1):1695–702.
23.Bahl M,
Qayyum A,
Westphalen AC,
Noworolski SM,
Chu PW,
Ferrell L,
et al.
Liver Steatosis: Investigation of Opposed-Phase T1-weighted Liver MR Signal Intensity Loss and Visceral Fat Measurement as Biomarkers.
Radiology.
2008 Oct;249(1):160–6.
24.Leporq B,
Dumortier J,
Pilleul F,
Beuf O.
3D-liver perfusion MRI with the MS-325 blood pool agent: a noninvasive protocol to asses liver fibrosis.
J Magn Reson Imaging.
2012 Jun;35(6):1380–7.
25.Materne R,
Smith AM,
Peeters F,
Dehoux JP,
Keyeux A,
Horsmans Y,
et al.
Assessment of hepatic perfusion parameters with dynamic MRI.
Magn Reson Med.
2002 Jan;47(1):135–42.
26.Hagiwara M,
Rusinek H,
Lee VS,
Losada M,
Bannan MA,
Krinsky GA,
et al.
Advanced liver fibrosis: diagnosis with 3D whole-liver perfusion MR imaging--initial experience.
Radiology.
2008 Mar;246(3):926–34.